08.08.26 -- Cell & Gene Newsletter - Best Of July

Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.

CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.

Discover how leading IDS teams are using automation and standardized digital workflows to streamline protocol management, reduce errors, improve efficiency, and strengthen research operations.

See how two academic investigators accelerated corneal regeneration and lung fibrosis therapies from preclinical research to clinical trials by leveraging scalable GMP solutions and regulatory-ready materials.

M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.